should glp-1 agonists be open access Frontiers GLP-1 receptor agonists | How

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of incretin-based therapies, are promising antidiabetic agents

In addition, while most group health plans (whether fully insured or self-funded) are subject to many federal laws, including the preventive-care mandates under the Affordable Care Act (learn more here), none require employers to cover GLP-1 drugs for either diabetes treatment or weight loss

faecalis supernatants were capable of disrupting the colonic epithelial monolayer and cleaving GLP-1 in a gelE-dependent manner (Levalley et al., 2020)

NamKoong, C

Kajikawa M, Higashi Y

[On-screen text: Are GLP-1s effective